Evidence map›Paper›PMID 35056119›Full record

ArticlePharmaceuticals (Basel, Switzerland)2022

Testing Mitochondrial-Targeted Drugs in iPSC-RPE from Patients with Age-Related Macular Degeneration.

Mara C Ebeling, Zhaohui Geng, Madilyn R Stahl, Rebecca J Kapphahn, Heidi Roehrich, Sandra R Montezuma, Deborah A Ferrington, James R Dutton

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mara C EbelingDepartment of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, MN 55455, USA.
Zhaohui GengStem Cell Institute, University of Minnesota, Minneapolis, MN 55455, USA.
Madilyn R StahlDepartment of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, MN 55455, USA.
Rebecca J KapphahnDepartment of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, MN 55455, USA.
Heidi RoehrichHistology Core for Vision Research, University of Minnesota, Minneapolis, MN 55455, USA.ORCID 0000-0002-2232-9494
Sandra R MontezumaDepartment of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, MN 55455, USA.
Deborah A FerringtonDepartment of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, MN 55455, USA.
James R DuttonStem Cell Institute, University of Minnesota, Minneapolis, MN 55455, USA.ORCID 0000-0002-5074-2614

Funding

Visual TestingP30EY011374 · NEI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI NEWMAN, ERIC A · 1996 to 2019
$8.8M
Mitochondrial defects in the retinal pigment epithelium and the CFH risk allele for age-related macular degenerationR01EY028554 · NEI · UNIVERSITY OF MINNESOTA · PI DUTTON, JAMES R., FERRINGTON, DEBORAH ANN · 2018 to 2025
$4.5M
NIH HHS P30EY11374NIH HHS R01EY028554
6 · The paper itself

Abstract

Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly. No universally effective treatments exist for atrophic or "dry" AMD, which results from loss of the retinal pigment epithelium (RPE) and photoreceptors and accounts for ≈80% of all AMD patients. Prior studies provide evidence for the involvement of mitochondrial dysfunction in AMD pathology. This study used induced pluripotent stem cell (iPSC) RPE derived from five AMD patients to test the efficacy of three drugs (AICAR (5-Aminoimidazole-4-carboxamide ribonucleotide), Metformin, trehalose) that target key processes in maintaining optimal mitochondrial function. The patient iPSC-RPE lines were used in a proof-of-concept drug screen, utilizing an analysis of RPE mitochondrial function following acute and extended drug exposure. Results show considerable variability in drug response across patient cell lines, supporting the need for a personalized medicine approach for treating AMD. Furthermore, our results demonstrate the feasibility of using iPSC-RPE from AMD patients to develop a personalized drug treatment regime and provide a roadmap for the future clinical management of AMD.

Indexed as

age-related macular degenerationhuman-induced pluripotent stem cellspersonalized drug testingretinal pigment epithelium

Identifiers

PMID35056119
PMCPMC8781759

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.